Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (NSCLC), ovarian cancer, or prostate cancer that has spread or cannot be removed with surgery, confirmed by laboratory testing of tissue samples.
• People who have already received at least one approved cancer treatment, and either have no remaining standard treatment options, are in a planned break between treatment courses, or (for prostate cancer) are currently stable on hormone-blocking therapy.
• People who are not currently receiving active cancer treatment, other than supportive care or hormone-blocking therapy for prostate cancer, and whose doctor does not expect them to need further approved cancer treatment for at least the first 8–9 weeks of the trial.
• People with NSCLC who have at least one tumour that can be clearly measured by CT or MRI scan at the start of the trial and monitored over time.
• People aged 18 to 75 years old.
• People who are reasonably able to carry out daily activities (as assessed by a standard medical scale called ECOG, with a score of 2 or less — confirm with trial site).
• People whose doctors expect them to live for at least 3 more months.
• People whose bone marrow, kidneys, and liver are functioning at an adequate level.

Who may not be able to join:

• People with a known history of significant problems with their immune system due to an underlying illness, or who have taken strong immune-suppressing medications (such as steroids above a certain dose) within the 14 days before the trial starts. Inhaled or skin-applied steroids, and steroids taken to replace hormones the body does not produce, are generally acceptable as long as there is no autoimmune disease present.
• People with a history of, or currently active, autoimmune disease (where the immune system attacks the body). Some milder conditions — such as vitiligo (skin pigment loss), type 1 diabetes, thyroid conditions managed only with hormone replacement, or psoriasis not requiring systemic treatment — may still be eligible (confirm with trial site).
• People who have received certain immune-based cancer treatments — including anti-cancer vaccines or specific types of immune checkpoint drugs — within the 28 days before the trial starts.
• People who have taken part in another clinical drug trial within 28 days, or within a longer period based on the specific drug used, before the trial starts.
• People who have had major surgery, chemotherapy, or radiation therapy for cancer within the 28 days before the trial starts.
• People who have an active infection currently requiring antibiotics or medical monitoring, or who have had repeated fevers above 38.0°C linked to an active infection.
• People who test positive for hepatitis B, hepatitis C (indicating active or ongoing infection), or HIV/AIDS. Testing for HIV is only required if there is a relevant medical history.
• People who have received any vaccine within 28 days before the trial starts.
• People who have had another cancer diagnosis within the past 3 years. Some exceptions may apply for early-stage cancers that were fully treated with curative intent, show no remaining signs of disease, and carry a very low risk of coming back (confirm with trial site).
• People who have brain metastases causing symptoms, or cancer that has spread to the membranes surrounding the brain and spinal cord.
• People with serious or poorly controlled medical conditions affecting the heart, lungs, kidneys, or immune system, which in the treating doctor's judgement could make participation unsafe or affect the trial results.
• People with a known allergy or sensitivity to any ingredient in the OVM-200 vaccine or its adjuvant (a substance added to boost the vaccine's effect).

Important: Always verify eligibility with the trial site directly before applying.